Generics in Canada - Market Research Report

TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Apotex Inc 19
Mylan Inc 20
Novartis AG 23
Teva Pharmaceutical Industries 26
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related MarketLine research 33

LIST OF TABLES
Table 1: Canada generics market value: $ million, 2007–11 8
Table 2: Canada generics market volume: % of total Pharma volume, 2007–11 9
Table 3: Canada generics market geography segmentation: $ million, 2011 10
Table 4: Canada generics market value forecast: $ million, 2011–16 11
Table 5: Canada generics market volume forecast: % of total Pharma volume, 2011–16 12
Table 6: Apotex Inc: key facts 19
Table 7: Mylan Inc: key facts 20
Table 8: Mylan Inc: key financials ($) 20
Table 9: Mylan Inc: key financial ratios 21
Table 10: Novartis AG: key facts 23
Table 11: Novartis AG: key financials ($) 24
Table 12: Novartis AG: key financial ratios 24
Table 13: Teva Pharmaceutical Industries: key facts 26
Table 14: Teva Pharmaceutical Industries: key financials ($) 27
Table 15: Teva Pharmaceutical Industries: key financial ratios 28
Table 16: Canada size of population (million), 2007–11 30
Table 17: Canada gdp (constant 2000 prices, $ billion), 2007–11 30
Table 18: Canada gdp (current prices, $ billion), 2007–11 30
Table 19: Canada inflation, 2007–11 31
Table 20: Canada consumer price index (absolute), 2007–11 31
Table 21: Canada exchange rate, 2007–11 31

LIST OF FIGURES
Figure 1: Canada generics market value: $ million, 2007–11 8
Figure 2: Canada generics market volume: % of total Pharma volume, 2007–11 9
Figure 3: Canada generics market geography segmentation: % share, by value, 2011 10
Figure 4: Canada generics market value forecast: $ million, 2011–16 11
Figure 5: Canada generics market volume forecast: % of total Pharma volume, 2011–16 12
Figure 6: Forces driving competition in the generics market in Canada, 2011 13
Figure 7: Drivers of buyer power in the generics market in Canada, 2011 14
Figure 8: Drivers of supplier power in the generics market in Canada, 2011 15
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Canada, 2011 16
Figure 10: Factors influencing the threat of substitutes in the generics market in Canada, 2011 17
Figure 11: Drivers of degree of rivalry in the generics market in Canada, 2011 18
Figure 12: Mylan Inc: revenues & profitability 21
Figure 13: Mylan Inc: assets & liabilities 22
Figure 14: Novartis AG: revenues & profitability 24
Figure 15: Novartis AG: assets & liabilities 25
Figure 16: Teva Pharmaceutical Industries: revenues & profitability 28
Figure 17: Teva Pharmaceutical Industries: assets & liabilities 29